Semler Scientific 2025 Q3 Earnings Record Net Income Surges 201.3%

Semler Scientific(SMLR), ranking by market capitalization reported its fiscal 2025 Q3 earnings on Nov 13th, 2025. The company delivered a significant net income surge despite a sharp revenue decline, with guidance for Q4 pointing to sequential revenue growth.

Semler Scientific reported a 44.6% year-over-year revenue decline to $7.49 million in Q3 2025, reflecting broader market challenges. However, the company raised its Q4 revenue outlook to $8.1–$8.3 million, signaling confidence in sequential improvement.

Revenue

Total revenue for Semler Scientific fell sharply to $7.49 million in Q3 2025, a 44.6% decrease from $13.51 million in the prior-year period.

Earnings/Net Income

The company’s earnings per share (EPS) rose 42.5% to $1.14, while net income surged 201.3% to $16.90 million, reflecting strong cost management and operational efficiency. This marks a significant improvement in profitability despite the revenue contraction.

Price Action

Post-Earnings Price Action Review

Following the earnings release, Semler Scientific’s stock price declined across multiple timeframes, tumbling 8.07% during the latest trading day. The downward trend intensified over the subsequent full trading week, with a 16.12% drop, and compounded to a 10.44% month-to-date decline. The sell-off suggests investor skepticism amid the revenue shortfall, despite the robust net income growth.

CEO Commentary

John Semler, CEO of Semler Scientific, highlighted robust Q3 performance driven by increased demand for the company’s advanced diagnostic solutions, particularly in the respiratory care segment. He emphasized operational efficiency and product innovation as key growth drivers, noting, “Our focus on high-margin product lines and streamlined manufacturing has delivered record net income of $16.9 million.” Challenges included supply chain constraints, which he stated were “progressively mitigated through diversified supplier partnerships.” Strategic priorities for 2025 included accelerating R&D in AI-integrated diagnostics and expanding market reach via strategic partnerships. Semler expressed an optimistic outlook, asserting, “We are well-positioned to capitalize on long-term industry tailwinds while maintaining disciplined cost management.”

Guidance

Semler Scientific guided to Q4 2025 revenue of $8.1–$8.3 million, reflecting sequential growth, with adjusted EPS projected at $1.20–

Additional News

No major non-earnings-related developments were reported for Semler Scientific within the three-week period surrounding its Nov 13, 2025, earnings release. The company did not announce M&A activity, C-level executive changes, or shareholder return programs during this timeframe.